{"title":"A patient-derived decellularized extracellular matrix hydrogel as a biomimetic scaffold for advanced 3D colorectal cancer modeling","authors":"Edoardo D'Angelo , Asia Marangio , Francesca Sensi , Eleonora Zanrè , Agostino Steffan , Ombretta Repetto , Riccardo Rampado , Monica Giomo , Matteo Fassan , Gaya Spolverato , Elisa Cimetta , Marco Agostini","doi":"10.1016/j.bioadv.2025.214438","DOIUrl":null,"url":null,"abstract":"<div><div>Colorectal cancer (CRC) is among the most prevalent cancers globally and is associated with a high mortality rate, particularly in advanced stages. In the realm of drug discovery, the use of innovative and highly translational pre-clinical CRC models is essential. Currently, the most relevant in vitro tumor approaches are three dimensional (3D) models. However, most 3D models of solid tumors are based either on synthetic materials or animal-derived commercial hydrogels, which fail to accurately mimic the biology of native tissues and originate from non-human sources. In contrast, hydrogels derived from human decellularized extracellular matrix (ECM) retain signaling cues from native tissue and represent a bioactive mechanical structure that can foster tumor cell growth in a tissue-specific 3D in vitro environment. Here, we demonstrated that patient-derived decellularized colon ECM can be processed into a hydrogel, producing the CologEM. CologEM formulation process preserved key ECM proteins, such as collagens, glycosaminoglycans and secreted bioactive molecules belonging to the family of cytokine, chemokine, interleukin, growth factors and ECM-remodeling enzyme. CologEM displayed a fibrous ultrastructure with interconnected pores, with notable differences observed between 1 % and 3 % (w/v) CologEM. Both 1 % and 3 % CologEM showed good biocompatibility, with 3 % CologEM demonstrating a higher propensity to induce a mesenchymal phenotype and resistance to antitumor drugs. In conclusion, CologEM is a suitable scaffold for 3D CRC models as it replicates critical characteristics of the tumor microenvironment. This model holds promise for facilitating the discovery and development of chemotropic drugs for cancer treatment.</div></div>","PeriodicalId":51111,"journal":{"name":"Materials Science & Engineering C-Materials for Biological Applications","volume":"178 ","pages":"Article 214438"},"PeriodicalIF":6.0000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Science & Engineering C-Materials for Biological Applications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772950825002651","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is among the most prevalent cancers globally and is associated with a high mortality rate, particularly in advanced stages. In the realm of drug discovery, the use of innovative and highly translational pre-clinical CRC models is essential. Currently, the most relevant in vitro tumor approaches are three dimensional (3D) models. However, most 3D models of solid tumors are based either on synthetic materials or animal-derived commercial hydrogels, which fail to accurately mimic the biology of native tissues and originate from non-human sources. In contrast, hydrogels derived from human decellularized extracellular matrix (ECM) retain signaling cues from native tissue and represent a bioactive mechanical structure that can foster tumor cell growth in a tissue-specific 3D in vitro environment. Here, we demonstrated that patient-derived decellularized colon ECM can be processed into a hydrogel, producing the CologEM. CologEM formulation process preserved key ECM proteins, such as collagens, glycosaminoglycans and secreted bioactive molecules belonging to the family of cytokine, chemokine, interleukin, growth factors and ECM-remodeling enzyme. CologEM displayed a fibrous ultrastructure with interconnected pores, with notable differences observed between 1 % and 3 % (w/v) CologEM. Both 1 % and 3 % CologEM showed good biocompatibility, with 3 % CologEM demonstrating a higher propensity to induce a mesenchymal phenotype and resistance to antitumor drugs. In conclusion, CologEM is a suitable scaffold for 3D CRC models as it replicates critical characteristics of the tumor microenvironment. This model holds promise for facilitating the discovery and development of chemotropic drugs for cancer treatment.
期刊介绍:
Biomaterials Advances, previously known as Materials Science and Engineering: C-Materials for Biological Applications (P-ISSN: 0928-4931, E-ISSN: 1873-0191). Includes topics at the interface of the biomedical sciences and materials engineering. These topics include:
• Bioinspired and biomimetic materials for medical applications
• Materials of biological origin for medical applications
• Materials for "active" medical applications
• Self-assembling and self-healing materials for medical applications
• "Smart" (i.e., stimulus-response) materials for medical applications
• Ceramic, metallic, polymeric, and composite materials for medical applications
• Materials for in vivo sensing
• Materials for in vivo imaging
• Materials for delivery of pharmacologic agents and vaccines
• Novel approaches for characterizing and modeling materials for medical applications
Manuscripts on biological topics without a materials science component, or manuscripts on materials science without biological applications, will not be considered for publication in Materials Science and Engineering C. New submissions are first assessed for language, scope and originality (plagiarism check) and can be desk rejected before review if they need English language improvements, are out of scope or present excessive duplication with published sources.
Biomaterials Advances sits within Elsevier''s biomaterials science portfolio alongside Biomaterials, Materials Today Bio and Biomaterials and Biosystems. As part of the broader Materials Today family, Biomaterials Advances offers authors rigorous peer review, rapid decisions, and high visibility. We look forward to receiving your submissions!